Abstract

Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents

Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski

Issue: Jul/Aug 2013 - Volume 17, Number 4

Page(s): 270-280

Download in electronic PDF format for $75

Abstract

Jet injection involves the use of a needle-free device that delivers a prescribed drug, vaccine, or compound intradermally, subcutaneously, or intramuscularly via high pressure produced by either a carbon-dioxide–filled or nitrogen-filled cartridge or a spring. During that procedure, the injector is held at an angle against the patient’s skin, and a very fine stream of liquid medication is forced through a tiny orifice in the device, penetrates the skin in a selected volume ranging from 0.05 mL to 1.0 mL, and is deposited in the underlying tissue. When compared with methods of injection that require a needle, jet injection offers multiple benefits. It can be less painful for the patient, and it enhances compliance, reduces risks such as needlestick injuries and cross-contamination, eliminates the need for “sharps” disposal, and enables (with minimal training) the reliable, reproducible, and accurate delivery of medication. Patient convenience is also a factor: Jet injectors are designed for self-medication as well as professional use. It must be remembered, however, that treatment via jet injection is not always painless. Because of their formulations, some medications and vaccines produce a burning or stinging sensation, whether they are administered with a jet injector or a needle. Some compounded preparations, like the formulations included in this article, can be administered by jet injection, a practice that we suggest will increase in popularity as more drugs are prescribed for administration in the home setting. Because changes in drug concentration may be required to effect the transfer of an agent or ensure the accurate reconstitution of a lyophilized drug administered with a jet injector, the skill of a compounding pharmacist will be essential in preparing customized injectates. In this article, we address the use of needle-free technology in general; present examples of carbon-dioxide, spring-powered, and novel jet injection systems; and answer questions of interest to compounders about the use of jet injectors.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2013 Pg. 270-280	Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski
Mar/Apr 2013 Pg. 100-110	Intravenous Needle-free Injection Devices: New Information for Compounding Pharmacists Author(s): Macklin Denise, Blackburn Paul L
Nov/Dec 2015 Pg. 491-500	Basics of Sterile Compounding: Sterile Product Packaging and Delivery Systems Author(s): Akers Michael J
Sep/Oct 2008 Pg. 463-466	Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration Author(s): Shields David E, Aclan Jennifer, Szatkowski Aaron
Mar/Apr 1997 Pg. 132-134	Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection Author(s): Zhang Yan-ping, Trissel Lawrence A
Mar/Apr 2014 Pg. 94-99	A Needle-free Reconstitution and Transfer System for Compounded Sterile Intravenous Drug Solutions: In Compliance with United States Pharmacopeia Chapter <797> Standards Author(s): Marks Zach
May/Jun 2016 Pg. 217-222	Basics of Sterile Compounding: Clinical Hazards of Injectable Drug Administration Author(s): Akers Michael J
May/Jun 2008 Pg. 200-207	Dilution and Compounding of Ziconotide for Intrathecal Administration Author(s): Buchta Tony, Fakata Keri, Stuart William
Mar/Apr 2008 Pg. 156-160	Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration Author(s): Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr
May/Jun 2015 Pg. 261-267	Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Author(s): Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
May/Jun 2006 Pg. 230-233	Compatibility of Micafungin Injection with Other Drugs During Simulated Y-Site Co-administration Author(s): Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Jul/Aug 1997 Pg. 274-277	Development of Clonidine HCl Injections for Epidural and Intrathecal Administration Author(s): Trissel Lawrence A, Xu Quanyun A, Hassebusch
Sep/Oct 1998 Pg. 382-384	Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump Author(s): Xu Quanyun A, Trissel Lawrence A
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
May/Jun 2022 Pg. 214-217	Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Mar/Apr 2012 Pg. 110-114	Bilateral Areolar Hyperpigmentation Following Transdermal Administration of Compounded Hormone Replacement Therapy Author(s): Griffee Chris, Delano Amy